In vitro and in vivo kinetics of recombinant vaccinia virus cancer-gene therapy

Eric Whitman, K. Tsung, J. Paxson, J. A. Norton, A. Shaked, H. K. Lyerly

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Background. Gene therapy of cancer is a promising therapeutic modality. Recombinant vaccinia viruses (RecVV), engineered to produce cytokines, may be effective in this area. This study's purpose was to investigate the kinetics of RecVV infection, measuring protein production and in vivo viral growth pattern. Methods. RecVV were constructed by homologous recombination, encoding murine interleukin-2 (mIL-2). After tumor cell infection, mIL-2 production was measured in vitro. Tumor-bearing and naive hosts were inoculated with RecVV and wild type vaccinia. Livers, spleens, and (where applicable) tumors were sequentially harvested, and tissue viral levels were measured. Results. Infected tumor cells made high levels of mIL-2 after infection with RecVV encoding for this cytokine. Naive mice were able to clear recombinant but not wild type VV from their livers and spleens by days 3 and 5, respectively. Tumor-bearing animals had persistent RecVV titers in the tumor tissue at day 8. Conclusions. RecVV can infect tumor cells, causing the production of a large amount of foreign protein but are attenuated relative to wild type virus in the murine host.

Original languageEnglish (US)
Pages (from-to)183-188
Number of pages6
JournalSurgery
Volume116
Issue number2
StatePublished - Jan 1 1994
Externally publishedYes

Fingerprint

Vaccinia virus
Neoplasm Genes
Genetic Therapy
Neoplasms
Interleukin-2
Spleen
Cytokines
Vaccinia
In Vitro Techniques
Liver
Homologous Recombination
Virus Diseases
Infection
Viral Load
Proteins
Viruses
Growth

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Whitman, E., Tsung, K., Paxson, J., Norton, J. A., Shaked, A., & Lyerly, H. K. (1994). In vitro and in vivo kinetics of recombinant vaccinia virus cancer-gene therapy. Surgery, 116(2), 183-188.
Whitman, Eric ; Tsung, K. ; Paxson, J. ; Norton, J. A. ; Shaked, A. ; Lyerly, H. K. / In vitro and in vivo kinetics of recombinant vaccinia virus cancer-gene therapy. In: Surgery. 1994 ; Vol. 116, No. 2. pp. 183-188.
@article{151ae443b3544b1f9ee987d6f3ee6194,
title = "In vitro and in vivo kinetics of recombinant vaccinia virus cancer-gene therapy",
abstract = "Background. Gene therapy of cancer is a promising therapeutic modality. Recombinant vaccinia viruses (RecVV), engineered to produce cytokines, may be effective in this area. This study's purpose was to investigate the kinetics of RecVV infection, measuring protein production and in vivo viral growth pattern. Methods. RecVV were constructed by homologous recombination, encoding murine interleukin-2 (mIL-2). After tumor cell infection, mIL-2 production was measured in vitro. Tumor-bearing and naive hosts were inoculated with RecVV and wild type vaccinia. Livers, spleens, and (where applicable) tumors were sequentially harvested, and tissue viral levels were measured. Results. Infected tumor cells made high levels of mIL-2 after infection with RecVV encoding for this cytokine. Naive mice were able to clear recombinant but not wild type VV from their livers and spleens by days 3 and 5, respectively. Tumor-bearing animals had persistent RecVV titers in the tumor tissue at day 8. Conclusions. RecVV can infect tumor cells, causing the production of a large amount of foreign protein but are attenuated relative to wild type virus in the murine host.",
author = "Eric Whitman and K. Tsung and J. Paxson and Norton, {J. A.} and A. Shaked and Lyerly, {H. K.}",
year = "1994",
month = "1",
day = "1",
language = "English (US)",
volume = "116",
pages = "183--188",
journal = "Surgery",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "2",

}

Whitman, E, Tsung, K, Paxson, J, Norton, JA, Shaked, A & Lyerly, HK 1994, 'In vitro and in vivo kinetics of recombinant vaccinia virus cancer-gene therapy', Surgery, vol. 116, no. 2, pp. 183-188.

In vitro and in vivo kinetics of recombinant vaccinia virus cancer-gene therapy. / Whitman, Eric; Tsung, K.; Paxson, J.; Norton, J. A.; Shaked, A.; Lyerly, H. K.

In: Surgery, Vol. 116, No. 2, 01.01.1994, p. 183-188.

Research output: Contribution to journalArticle

TY - JOUR

T1 - In vitro and in vivo kinetics of recombinant vaccinia virus cancer-gene therapy

AU - Whitman, Eric

AU - Tsung, K.

AU - Paxson, J.

AU - Norton, J. A.

AU - Shaked, A.

AU - Lyerly, H. K.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Background. Gene therapy of cancer is a promising therapeutic modality. Recombinant vaccinia viruses (RecVV), engineered to produce cytokines, may be effective in this area. This study's purpose was to investigate the kinetics of RecVV infection, measuring protein production and in vivo viral growth pattern. Methods. RecVV were constructed by homologous recombination, encoding murine interleukin-2 (mIL-2). After tumor cell infection, mIL-2 production was measured in vitro. Tumor-bearing and naive hosts were inoculated with RecVV and wild type vaccinia. Livers, spleens, and (where applicable) tumors were sequentially harvested, and tissue viral levels were measured. Results. Infected tumor cells made high levels of mIL-2 after infection with RecVV encoding for this cytokine. Naive mice were able to clear recombinant but not wild type VV from their livers and spleens by days 3 and 5, respectively. Tumor-bearing animals had persistent RecVV titers in the tumor tissue at day 8. Conclusions. RecVV can infect tumor cells, causing the production of a large amount of foreign protein but are attenuated relative to wild type virus in the murine host.

AB - Background. Gene therapy of cancer is a promising therapeutic modality. Recombinant vaccinia viruses (RecVV), engineered to produce cytokines, may be effective in this area. This study's purpose was to investigate the kinetics of RecVV infection, measuring protein production and in vivo viral growth pattern. Methods. RecVV were constructed by homologous recombination, encoding murine interleukin-2 (mIL-2). After tumor cell infection, mIL-2 production was measured in vitro. Tumor-bearing and naive hosts were inoculated with RecVV and wild type vaccinia. Livers, spleens, and (where applicable) tumors were sequentially harvested, and tissue viral levels were measured. Results. Infected tumor cells made high levels of mIL-2 after infection with RecVV encoding for this cytokine. Naive mice were able to clear recombinant but not wild type VV from their livers and spleens by days 3 and 5, respectively. Tumor-bearing animals had persistent RecVV titers in the tumor tissue at day 8. Conclusions. RecVV can infect tumor cells, causing the production of a large amount of foreign protein but are attenuated relative to wild type virus in the murine host.

UR - http://www.scopus.com/inward/record.url?scp=0027971239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027971239&partnerID=8YFLogxK

M3 - Article

VL - 116

SP - 183

EP - 188

JO - Surgery

JF - Surgery

SN - 0039-6060

IS - 2

ER -

Whitman E, Tsung K, Paxson J, Norton JA, Shaked A, Lyerly HK. In vitro and in vivo kinetics of recombinant vaccinia virus cancer-gene therapy. Surgery. 1994 Jan 1;116(2):183-188.